KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Net Margin (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Net Margin data on record, last reported at 244.79% in Q4 2025.

  • For Q4 2025, Net Margin fell 10108.0% year-over-year to 244.79%; the TTM value through Dec 2025 reached 188.09%, down 11141.0%, while the annual FY2025 figure was 188.09%, 11141.0% down from the prior year.
  • Net Margin reached 244.79% in Q4 2025 per AQST's latest filing, down from 120.61% in the prior quarter.
  • Across five years, Net Margin topped out at 72.46% in Q1 2023 and bottomed at 618.35% in Q2 2021.
  • Average Net Margin over 5 years is 143.5%, with a median of 112.59% recorded in 2021.
  • Peak YoY movement for Net Margin: skyrocketed 41458bps in 2022, then crashed -17889bps in 2024.
  • A 5-year view of Net Margin shows it stood at 261.28% in 2021, then skyrocketed by 56bps to 115.63% in 2022, then skyrocketed by 47bps to 61.42% in 2023, then plummeted by -134bps to 143.72% in 2024, then tumbled by -70bps to 244.79% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 244.79% in Q4 2025, 120.61% in Q3 2025, and 135.44% in Q2 2025.